We use some essential cookies to make this website work. These cookies are used to improve your website experience. To find out more about the cookies we use, see our Privacy Policy.
We’d also like to use analytics cookies so we can understand how you use the service and make improvements.
Use these toggles to accept or reject individual cookies. To find out more about the cookies we use, see our Privacy Policy.
Advanced analytics
Predict drug efficacy in preclinical models & in individual patients using astrophysics-grade Bayesian AI, so you can choose indications, patients and trial designs on biological evidence.
Develop a winning Target Product Profile (TPP) with indication prioritisation and biomarker strategy, before Phase I
Each patient gets a molecular twin that predicts response to standard of care and to your asset. Measure benefit per patient, enrich for likely responders, and size trials on real biology.
Accelerate companion diagnostic development with traceable biological evidence designed to support regulatory and payer review, including head-to-head evidence against standard of care for HTA.
Help us enable biopharma, diagnostics and healthcare industries to discover better ways to overcome cancer.
Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.
Our growth is powered by funding and hands-on support from across three continents.
